Exelixis (NASDAQ:EXEL) Rating Increased to Hold at Zacks Research

Posted by Stanley Muller on Sep 3rd, 2026

Exelixis (NASDAQ:EXEL – Get Free Report) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Tuesday, Zacks reports.

A number of other brokerages have also weighed in on EXEL. Citizens Jmp boosted their price objective on shares of Exelixis from $50.00 to $55.00 and gave the stock a “market outperform” rating in a report on Wednesday, June 24th. UBS Group set a $55.00 target price on Exelixis in a report on Monday, August 3rd. BMO Capital Markets started coverage on Exelixis in a report on Tuesday, August 18th. They set a “market perform” rating and a $54.00 price target on the stock. TD Cowen increased their price objective on Exelixis from $51.00 to $55.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Finally, Citigroup reiterated a “market outperform” rating on shares of Exelixis in a report on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $50.07.

Check Out Our Latest Report on EXEL

Exelixis Trading Up 2.9%

Exelixis stock opened at $58.53 on Tuesday. Exelixis has a 12 month low of $33.76 and a 12 month high of $59.11. The company has a market capitalization of $14.50 billion, a price-to-earnings ratio of 18.41, a price-to-earnings-growth ratio of 1.69 and a beta of 0.42. The business’s fifty day simple moving average is $54.86 and its two-hundred day simple moving average is $49.33.

Exelixis (NASDAQ:EXEL – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.06. The firm had revenue of $628.69 million during the quarter, compared to analyst estimates of $636.40 million. Exelixis had a return on equity of 42.17% and a net margin of 35.33%.Exelixis’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.75 EPS. On average, equities research analysts predict that Exelixis will post 3.19 EPS for the current year.

Insiders Place Their Bets

In other Exelixis news, Director Mary C. Beckerle sold 9,812 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $53.66, for a total value of $526,511.92. Following the transaction, the director directly owned 16,079 shares of the company’s stock, valued at approximately $862,799.14. This trade represents a 37.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 2.60% of the company’s stock.

Institutional Trading of Exelixis

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Motiv8 Investments LLC purchased a new position in shares of Exelixis during the 4th quarter worth $26,000. Cassaday & Co Wealth Management LLC purchased a new stake in shares of Exelixis in the 1st quarter worth $27,000. Acumen Wealth Advisors LLC purchased a new stake in shares of Exelixis in the 4th quarter worth $29,000. Western Wealth Management LLC bought a new position in Exelixis in the 1st quarter worth $29,000. Finally, Northwestern Mutual Wealth Management Co. raised its holdings in Exelixis by 1,380.4% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 829 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 773 shares during the period. 85.27% of the stock is owned by hedge funds and other institutional investors.

Exelixis Company Profile

(Get Free Report)

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.